Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 15/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 13/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.53 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | BMP4 | P12644 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10235403 | 0.82 | JAK1 (0.37) | ACVR2ATGFBR2TGFBR1JAK1JAK3 | |
| SCHEMBL10234136 | 0.82 | JAK1 (0.40) | ACVR2ATGFBR2TGFBR1JAK1JAK3 | |
| SCHEMBL10182966 | 0.80 | ACVR2A (0.47) | ACVR2ATGFBR2TGFBR1JAK1JAK3 | |
| SCHEMBL10234979 | 0.72 | JAK1 (0.38) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL22313787 | 0.72 | SLC13A5 (0.45) | ACVR2ATGFBR2TGFBR1SLC13A5 | |
| SCHEMBL30626327 | 0.71 | LOX (0.55) | ACVR2ATGFBR2TGFBR1SLC13A5 | |
| SCHEMBL16116782 | 0.71 | LOX (0.55) | ACVR2ATGFBR2TGFBR1SLC13A5 | |
| SCHEMBL23425908 | 0.70 | EPHB3 (0.42) | — | |
| SCHEMBL16459051 | 0.70 | JAK1 (0.50) | ACVR2ATGFBR2TGFBR1JAK1JAK3 | |
| SCHEMBL14072379 | 0.69 | LOX (0.47) | ACVR2ATGFBR2TGFBR1SLC13A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ACVR2A 3694/4885TGFBR2 3200/4885TGFBR1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.